Advertisement
News
Advertisement

Haemonetics acquisition delayed by FDA setback

Thu, 09/27/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Haemonetics (NYSE: HAE), a blood management company, must delay the closing of its acquisition of Hemerus Medical, after the U.S. Food and Drug Administration delayed approval of a Hemerus product. The acquisition is contingent on the FDA approval.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading